< Terug naar vorige pagina
Onderzoeker
Thomas Morel
- Disciplines:Gastro-enterologie en hepatologie, Immunologie, Pediatrie en neonatologie, Verpleegkunde
Affiliaties
- Hepatologie (Afdeling)
Lid
Vanaf1 apr 2019 → 31 mrt 2022 - Klinische Farmacologie en Farmacotherapie (Afdeling)
Lid
Vanaf1 jul 2013 → 31 mrt 2019
Projecten
1 - 1 of 1
- Weesziekten en Weesgeneesmiddelen: wat telt voor de patiënten, hoe evolueert de markt en wat zijn de misvattingen.Vanaf1 okt 2013 → 11 jan 2019Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
11 - 20 van 22
- Coverage of orphan drugs(2017)
Auteurs: Thomas Morel, Steven Simoens
Pagina's: 109 - 121 - Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™(2016)
Auteurs: Thomas Morel
Pagina's: 3017 - 3024 - The orphan drug pipeline in Europe(2016)
Auteurs: Thomas Morel, David Cassiman
Pagina's: 376 - 376 - Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers(2016)
Auteurs: Thomas Morel, David Cassiman, Steven Simoens, Martina Vandebroek
- Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers(2016)
Auteurs: Thomas Morel, S Aymé, David Cassiman, Steven Simoens, M Morgan, Martina Vandebroek
- Publication practices and standards: recommendations from GSK Vaccines' author survey(2014)
Auteurs: Thomas Morel
- A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome(2014)
Auteurs: Thomas Morel
Pagina's: 2267 - 2278 - Shining a light in the black box of orphan drug pricing(2014)
Auteurs: Eline Picavet, Thomas Morel, David Cassiman, Steven Simoens
Pagina's: 62 - Market watch: Are orphan drug companies the pick of the pharmaceutical industry?(2014)
Auteurs: Thomas Morel, Steven Simoens
Pagina's: 10 - 10 - Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries(2013)
Auteurs: Thomas Morel, Francis Arickx, Gustaf Befrits, Paolo Siviero, Caroline van der Meijden, Entela Xoxi, Steven Simoens
Pagina's: 1 - 15